Shareholders Approve All Resolutions at iCo Therapeutics Annual General Meeting
June 8, 2009
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) (“iCo” or “the Company”) today announced that all matters considered by shareholders at the Company’s annual general meeting on June 5, 2009 (the “AGM”) were approved.
The following individuals were elected to iCo’s Board of Directors:
• Chairman: William Jarosz, Co-Founder, Partner Cartesian Capital Group, LLC
• Noel Hall, Co-Founder, Aspreva Pharmaceuticals Corporation
• Richard Barker, Director General of the Association British Pharmaceutical Industry
• Andrew Rae, President & Chief Executive Officer, iCo Therapeutics
• John Clement, Chief Business Officer, iCo Therapeutics
At the AGM, shareholders also approved a resolution to amend the Company’s 2007 Stock Option Plan (the “Stock Option Plan”) to increase the number of common shares reserved for issuance pursuant to the exercise of stock options from 2,686,977 common shares to 3,200,000 common shares. Under the rules of the TSX Venture Exchange, the number of shares reserved for issuance under a stock option plan must not exceed 20% of a company’s issued and outstanding share capital. The number of common shares reserved for issuance under the Stock Option Plan will represent 11.34% of the currently issued and outstanding common shares of the Company. The proposed amendment to the Stock Option Plan is subject to the approval of the TSX Venture Exchange.
